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The differential susceptibility of skeletal muscle by myasthenia gravis (MG) is not
well understood. We utilized RNA expression profiling of extraocular muscle (EOM),
diaphragm (DIA), and extensor digitorum (EDL) of rats with experimental autoimmune
MG (EAMG) to evaluate the hypothesis that muscles respond differentially to injury
produced by EAMG. EAMG was induced in female Lewis rats by immunization with
acetylcholine receptor purified from the electric organ of the Torpedo. Six weeks
later after rats had developed weakness and serum antibodies directed against the
AChR, animals underwent euthanasia and RNA profiling performed on DIA, EDL, and
EOM. Profiling results were validated by qPCR. Across the three muscles between the
experiment and control groups, 359 probes (1.16%) with greater than 2-fold changes
in expression in 7 of 9 series pairwise comparisons from 31,090 probes were identified
with approximately two-thirds being increased. The three muscles shared 16 genes with
increased expression and 6 reduced expression. Functional annotation demonstrated
that these common expression changes fell predominantly into categories of metabolism,
stress response, and signaling. Evaluation of specific gene function indicated that EAMG
led to a change to oxidative metabolism. Genes related to muscle regeneration and
suppression of immune response were activated. Evidence of a differential immune
response among muscles was not evident. Each muscle had a distinct RNA profile
but with commonality in gene categories expressed that are focused on muscle repair,
moderation of inflammation, and oxidative metabolism.
Keywords: myasthenia gravis, acetylcholine receptor, autoimmunity, gene expression profiles, skeletal muscle,
metabolism
INTRODUCTION
Myasthenia gravis (MG) is caused by antibodies, primarily directed at skeletal muscle nicotinic
acetylcholine receptor (AChR), which lead to a reduction of AChR number and damage of the
muscle endplate, producing a failure of neuromuscular transmission that results in weakness (Engel
et al., 1976). The pathophysiology would be expected to compromisemuscles to a similar extent, but
Kaminski et al. RNA Profile of Experimental Myasthenia
clinical investigation for over a 100 years have demonstrated
a preferential involvement of certain muscles. Explanations
for the differential targeting may lie in subtle aspects of the
antibody-antigen engagement in vivo but are more likely to entail
variations in the properties of the targeted muscles.
The differential involvement of skeletal muscles by
neuromuscular disorders, including MG, is poorly understood
but likely is a function of disease specific pathophysiology and
properties of the individual muscles. In particular, differences in
functional requirements of a muscle impact the gene expression
pattern. In its role in eye movement extraocular muscle (EOM)
is constantly, and this is reflected in its transcriptional profile
differing from jaw and leg muscle in expression of glycogenic
and gluconeogenic genes (Porter et al., 2001; Fischer et al.,
2005). Further, lactate is a significant substrate for EOM,
which is in stark contrast to other skeletal muscles that excess
lactate produces fatigue (Andrade and McMullen, 2006).
Similarly, as reflected in fiber-type distribution diaphragm also
possess properties that support its high energy requirements
compared to leg muscles (Polla et al., 2004). The consequences of
neuromuscular disorders on whole body metabolism may then
also be expected to differentially impact muscles.
Extraocular muscle (EOM) are preferentially involved by MG
and several non-exclusive explanations have been proposed. A
patient may develop dramatic double vision with even minimal
weakness of an EOM, but a similar level of weakness of
another muscle would not produce clinically evident symptoms.
The extremely rapid firing rate of ocular motor neurons and
the immature appearance of their neuromuscular junctions
may place the EOM at particular risk for a neuromuscular
transmission disorder. The RNA expression profiles of EOM,
extensor digitorum longus (EDL), and diaphragm (DIA) muscle
from rats with passively-transferred MG (PTMG) (Kusner et al.,
2015) produced by administration of acetylcholine receptor
antibody supports a greater degree of injury to EOM (Zhou
et al., 2014), which supports that EOMhas unique immunological
characteristics that places them at specific risk for MG (Kaminski
et al., 2004; Soltys et al., 2008; Pedrosa Domellof, 2013).
EAMG induced in rodents by immunization with
purified AChR mimics the human disease much better than
administration of AChR antibodies (Losen et al., 2015). Within 6
weeks of a single immunization, rats generate AChR antibodies
and then weakness, which improves with cholinesterase
inhibition. As with humans, infiltrates of inflammatory cells are
not prominently observed in muscle (Nakano and Engel, 1993;
Baggi et al., 2012), which is in contrast to PTMG. In order to
assess, variations in intrinsic response of muscles to EAMG, we
used RNA expression profiling of diaphragm (DIA), extensor
digitorum longus (EDL), and EOM to assess their response.
MATERIALS AND METHODS
Ethics Statement for Animal Use
Six to eight week old female Lewis rats weighing 120–150 g
(Harlan, Indianapolis, IN) were maintained in the Case Western
Reserve University School of Medicine animal facility. The
animal facility follows IACUC, AAALAT, and AALAS standards
concerning appropriate housing, cage cleaning procedure, air
purity, feed, temperature, humidity, light and dark cycle. Animals
were housed in isolator cages in a pathogen-free environment,
and rodent chow and water were provided ad libitum. A
veterinarian is on staff and will be observing the health of the
animals throughout the study. All animal studies were conducted
according to protocol approved by the Case Western Reserve
Institutional Animal Care and Use Committee Approval Number
030185. All efforts were made to minimize animal suffering.
Tissue was harvested after euthanasia by CO2 asphyxiation.
Induction and Evaluation of EAMG
Torpedo AChR was purified from the electric organ of
Torpedo californica by affinity chromatography as previously
described (Lindstrom et al., 1983). Rats were immunized
once at the base of the tail by subcutaneous injection of
purified Torpedo AChR (40µg/rat in 200µl) emulsified in
complete Freund’s adjuvant supplemented with additional non-
viable Mycobacterium tuberculosis H37RA (0.5mg/rat; Difco
Laboratories, Detroit, MI). Control rats were immunized with the
same volume of adjuvant without AChR. Rats were monitored
for evidence of weakness and their status scored based on a
commonly used motor strength scale, as follows: 0 = can grip
and lift lid of a cage, 1= can grip but cannot lift the lid of a cage,
2 = unable to grip cage lid, 3 = unable to grip and has hind limb
paralysis, 4 = moribund. Weight was assessed initially on a bi-
weekly basis and then every other day when weakness or weight
loss became evident.
Tissue Preparation
After euthanasia, EOM rectus muscles, DIA, and EDL muscles
were dissected from rats 6 weeks after initiation of the
experiment.Muscles were pooled from 4 to 5 rats for each of three
independent replicate groups. The study was then repeated twice
to produce the 3 replicates for the array analysis. This procedure
served to limit inter-animal and inter-experiment variability.
Tissues were snap frozen in liquid nitrogen and stored at −80◦C
until use.
Serum AChR Antibody Determination
Blood was obtained at week 2 by tail vein puncture and after
euthanasia from the heart at week 6. Serum was isolated and
AChR antibody determination made by ELISA. Ninety-six-well
immune-plates (Corning; New York, NY) were saturated with
200µl (10µg/ml AChR) in PBS buffer (0.1% Tween20 in PBS)
per well and incubated overnight at 4◦C. After washing twice with
PBST buffer, the plates were incubated with 200µl of blocking
buffer (5% of bovine serum albumin in PBS) per well at 37◦C for
0.5–1.5 h. The plates were washed twice with PBST buffer and
then incubated for 1 h at 37◦C with 100µl of the diluted test
serum (1:200). The plates were then washed twice with PBST,
each well received 100µl of peroxidase-labeled rabbit anti-rat
IgG and incubated for 1 h at 37◦C. One hundred microliter of
substrate solution [0.05M citrate, 0.1M NaCl/Pi, 2,20-Azino-
bis(3-ethylbenzothiazoline-6-sulfonic acid), 0.03% H2O2] was
incubated for 15min at 37◦C. Color development was measured
at 405 nm using a microplate reader.
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Immunohistochemistry
For analysis of C9 deposition at neuromuscular junctions,
cryosections of muscles were prepared. Sections were incubated
with rabbit anti-ratC9 (gift of M. E. Medof) and then double-
stained with FITC-labeled goat anti-rabbit Ab and Texas
red–labeled αBTX (2µg/ml; Molecular Probes Inc., Eugene,
Oregon, USA) to identify neuromuscular junctions. Sections
were examined with a Nikon Diaphot fluorescence microscope
(Nikon Instruments Inc., Melville, New York, USA) and analyzed
using ImagePro software (Media Cybernetics, Silver Spring,
Maryland, USA).
Sample Preparation for Microarrays
The muscle harvested from DIA, EDL, and EOM of four
rats pooled from four EAMG or control rats during RNA
isolation forming three samples for subsequent array analysis.
Total RNA was extracted using TRIzol reagent (GibcoBRL,
Rockville, MD). RNA pellets were cleaned by RNasey kits and
re-suspended at 1mg RNA/ml DEPC-treated water and 5µg
was used in a reverse transcription reaction (SuperScript II; Life
Technologies, Rockville, MD) to generate first strand cDNA.
Double strand cDNA was synthesized and used in an in vitro
transcription (IVT) reaction to generate biotinylated cRNA.
Fragmented cRNA (15µg) was used in a 300µl hybridization
cocktail containing herring sperm DNA and BSA as carrier
molecules, spiked IVT controls, and buffering agents. A 200µl
aliquot of this cocktail was used for hybridization to Affymetrix
rat REA230 (Santa Clara, CA) microarrays for 16 h at 45◦C.
The manufacturer’s standard post-hybridization wash, double-
stain, and scanning protocols used an Affymetrix GeneChip
Fluidics Station 400 and a Hewlett Packard Gene Array
scanner.
Microarray Data Analysis
Raw data from microarray scans were analyzed with Affymetrix
GCOS 2.0. GCOS evaluates sets of perfect match (PM) and
mismatch (MM) probe sequences to obtain both hybridization
signal values and present/absent calls for each transcript.
Microarrays were scaled to the same target intensity and
pairwise comparisons were made between experimental and
control samples. Transcripts defined as differentially regulated
met the criteria of: (a) consistent increase/decrease call across 7
out of 9 replicate comparisons, based upon Wilcoxon’s signed
rank test (algorithm assesses probe pair saturation, calculates
a p-value and determines increase, decrease, or no change
calls). Any transcripts with expression intensity below 400 (5
time of background level) across all the samples were also
excluded since distortion of fold difference values results when
expression levels are low and may be within the level of
background noise. Data were visualized as a hierarchical cluster
analysis generated (Genespring software, version 7.2; Silicon
Genetics, Redwood city, CA). Annotation was done according
to Affymetrix NetAffyx Gene Ontology database. Data for the
18 microarray experiments used in this report can be found in
the National Center for Biotechnology Information (NCBI) Gene
Expression Omnibus (GEO), series accession number GSE11465.
Quantitative Real-Time PCR (qPCR)
Select transcripts were reanalyzed by qPCR, using the same
samples as in the microarray studies. Transcript-specific primers
(Supplemental Table 1) were designed using Primer Express 2.0
software [Applied Biosystems, Inc. (ABI), Foster City, CA] and
specificity confirmed by NCBI BLAST. Reverse transcription was
carried out on 1 µg total RNA with In vitro Reverse transcription
reagent. qRT-PCR used SYBR green PCR core reagent in 24 µl
volume, with an ABI PRISM 7000 Sequence Detection System.
GAPDH was used as an internal positive loading control. Fold
change values represent averages from triplicate measurements,
using the 2−11CT method (Simon, 2003).
RESULTS
Confirmation of EAMG Induction
After the immunization, serum AChR antibody levels of the
experimental group were 2.5µg/ml ± 1.1 (2 weeks) and
8.05µg/ml ± 3.38 (6 weeks). AChR antibody was undetectable
in the control group throughout the experiment, while all
rats in the experimental group developed elevations of AChR
antibody levels. At weeks 4–5, weight loss was observed in EAMG
rats and weakness became evident as assessed by reductions
of grip strength and reduction of observed movement (data
not shown). At week 6 experimental rats had a mean weight
loss of 11.5% ± 3.45 compared to their peak weight, while
control rats had a mean weight gain of 5.9% ±1.0 compared
to the previous week weight. All rats reached the end of
the experiment with no need for early euthanasia. To assess
for activation of the complement system, we evaluated C9
deposition from control and experimental rats. Endplates from
all control muscles had α-BTX staining and no C9 staining.
Endplates from all EAMG muscles demonstrated endplates
C9 deposition which overlapped with α-BTX fluorescence
(not shown).
RNA Profile Analysis
To identify global alterations in gene expression related to EAMG
in EOM, DIA, and EDL, RNA was prepared and processed for
microarray hybridization from AChR immunized and control
CFA immunized rats. The percentage of transcripts detected as
present in each sample ranged from 48 to 63.7 with average 53.3
± 4.2. The GAPDH probes 3–5 ratio ranged from 1.06 to 2.66
with average 1.27± 0.35, indicating RNA quality was appropriate
and the hybridization was successful among the samples. The
results are consistent with our previous expression profiling
studies (Zhou et al., 2014).
We found a total of 359 transcripts (Figure 1) altered
by 2-fold in 7 of 9 series pairwise comparisons between
the experimental and control groups among the muscles.
Figure 1 shows the degree of overlap in gene differences
across the three muscles. DIA showed 147 gene changes, 85
genes were up-regulated and 62 down-regulated, EDL had
205 genes changed, 100 were up-regulated and 105 down-
regulated, and EOM have 116 changed, 85 are up-regulated
and 31 down-regulated. Using the 359 transcripts, hierarchical
cluster analysis (Figure 2) demonstrated a distinct expression
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FIGURE 1 | Venn diagrams showing the numbers of differentially
expressed transcripts in EAMG muscles compared with control rats
shared by or unique to DIA, EDL, and EOM.
pattern of the genes found to be differentially influenced
by EAMG across the three muscles. Comparison of the
differentially expressed transcripts identified 16 upregulated
and 6 downregulated transcripts shared among the three
muscles (Table 1). Functional annotation of the differentially
expressed genes identified more than a half are involved in
signal transduction, metabolism and transcription regulation,
suggesting the muscles experience adaptation to EAMG directly
and to metabolic alterations associated with the disease (Table 2,
Supplemental Table 2). Alteration of expression of 10 genes
(Enc1, Nfkbia, Nfix, Errfi1, Glipr2, Dyrk2, Hbb, Hba-a1, Pnpla2,
Galnt12) were identified common to the three muscles as a
response to EAMG. The roles of these genes fell into two
broad categories: muscle repair and suppression of inflammatory
signals. The Discussion provides detailed consideration of
expression alterations.
In our previous study of passive transfer MG and a study
of mdx mice (Porter et al., 2003a; Zhou et al., 2014), we
determined a disease load index (DLI), which sums the absolute
FIGURE 2 | Hierarchical cluster analysis using 359 gene probes
identified as differentially expressed in EAMG among DIA, EDL, and
EOM. The three independent replicates of each group are represented.
Expression ratios are color-coded. The scale at the right denotes normalized
expression levels (red, high expression; blue, low expression).
fold change values of increased and decreased transcript to
provide a single transcriptional index of EAMG pathology. In
the present investigation, EDL had the greatest DLI (Figure 3),
although EOMhad the greatest total of increased transcript levels
with 351 total fold increase to 101 total fold decrease. The greater
DLI of EDL suggests a greater transcriptional response to EAMG
than EOM or DIA.
Validation of RNA Profile
We used qPCR to validate results of the RNA profiling. We
determined expression levels of 14 transcripts to provide a broad
assessment of the array results. Three upregulated transcripts
(Ankrd1, Mt1a, Cebpd1) and one down regulated transcript
(Neu2) that by RNA profiling had been identified as altered
across all three muscles. We assessed transcripts that were
previously identified as altered by EAMG (Chrna1, Pde4b, Cts1,
Trm63) (Mizrachi et al., 2010; Zhou et al., 2014) or involved in
inflammation (NFκB, Ctse). We evaluated transcripts that were
increased in the RNA profiling of EOM alone (Plunc, Pax6, Rgs2)
(Porter et al., 2003b) or known to be increased in EOM (Csrp3)
(Diehl et al., 2006). RNA profiling and qPCR results correlated
well with correlation coefficient of 0.9 (Table 3).
DISCUSSION
We found distinct genomic signatures for DIA, EDL, and
EOM in response to EAMG with a small number of gene
alterations shared among the muscles (Figure 1). The results
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TABLE 1 | Gene transcript changes common to all muscles.
Symbol Name DIA EDL EOM Classification
Ankrd1 Ankyrin repeat domain 1 5.6 5.5 3.6 Transcription
Cebpd CEBP delta 2.9 8.4 2.5 Transcription
Nfix Nuclear factor I/X −4.7 −2.0 −2.9 Transcription
Nfkbia Nuclear factor of kappa light chain 2.3 2.8 2.3 Transcription
Ddit4 DNA-damage-inducible transcript 4 3.1 4.7 3.1 Stress
Gadd45a Growth arrest and DNA-damage-inducible 45 alpha 2.3 2.1 2.5 Stress
Mt1a Metallothionein 1a 4.7 8.2 3.3 Stress
Errfi1 ERBB receptor feedback inhibitor 1 2.9 3.0 2.8 Stress
Mt1e Metallothionein 1e 3.0 5.5 2.8 Stress
Gpnmb Glycoprotein (transmembrane) nmb 2.2 3.1 5.2 Signal
Glipr2 Golgi- associated PR-1 protein −2.4 −2.4 −2.2 Signal
Dyrk2 Dual specificity tyrosine-phosphorylation-regulated kinase 2 −2.4 −2.3 −2.4 Signal
Enc1 Ectodermal-neural cortex 1 2.4 2.1 2.1 Signal
Hbb Hemoglobin beta chain complex −4.8 −2.4 −3.9 Metabolism
Neu2 Neuraminidase 2 −2.9 −4.0 −2.2 Metabolism
Hba-a1 Hemoglobin alpha 2 chain −3.6 −2.3 −3.5 Metabolism
Pnpla2 Patatin-like phospholipase domain containing 2 2.4 2.8 2.1 Metabolism
pdk4 Pyruvate dehydrogenase 2.4 3.5 2.3 Metabolism
fmo2 Flavin containing monooxygenase 2 4.0 3.0 3.9 Metabolism
galnt12 GalNAc transferase 12 3.5 2.8 2.6 Metabolism
Angptl4 Angiopoietin-like 4 6.4 6.2 17.5 Metabolism
Fkbp5 FK506 binding protein 5 4.5 5.3 5.6 Immune
TABLE 2 | Transcript changes in percent by category.
Shared EOM DIA EDL
Transcription 18 5 7 19
Stress 22 0 1 5
Metabolism 32 21 6 17
Signaling 18 33 44 25
Proteolysis 0 5 4 5
Muscle-related 0 4 1 5
Inflammatory 5 8 7 2
*ECM 5 3 0 2
EST/Unknown 0 21 30 20
*Extracellular Matrix.
of array analysis were validated by qPCR with a significant
correlation. Across the muscles, there was wide variation
in the specific gene changes, but a commonality of genes
that were altered occurred in cell signaling, transcriptional
factors, and metabolism categories. Genes associated with
muscle injury repair were upregulated. Only, a few genes
primarily associated with the immune system or inflammation
were modified by EAMG, however these were focused on
genes that would suppress inflammation. The observation
is consistent with histology of muscle of human MG, and
EAMG in the chronic stage, which does not have evidence
of inflammation (Nakano and Engel, 1993; Losen et al., 2015;
Tuzun et al., 2015). The expression of immunosuppressive genes
provides the first insight into why EAMG, by extension human
MG, lacks inflammatory infiltrates in muscle after the acute
induction stage.
A critical issue that cannot be addressed by our investigation is
the degree to which individual mechanisms alter transcriptional
profiles. For example, reduced muscle activity produced
by EAMG, or for that matter, passive transfer MG in
our previous investigation influences the gene expression
pattern. The EOM in particular have unique neuromuscular
transmission properties with synapses subject to extremely high
stimulation rates by their motor neurons and a reduction
in muscle stimulus would likely lead to transcriptional
alterations (Spencer and Porter, 2005). Knowing that post-
synaptic damage is likely to influence presynaptic properties,
we cannot dissociate our results to one specific alteration
produced by EAMG (Ouanounou et al., 2016). As we discuss
the influence of alterations in whole body metabolism
produced by weight loss further will alter gene expression
of each muscle in a differential pattern given their unique
characteristics.
Gene Expression Alterations Unique to
EAMG and Common to All Muscles
The enhanced expression of five genes (Nfix, Enc, Errfi1,
Glipr2, Dyrk2, Galnt12) modified by EAMG appear to enhance
muscle repair. Nfix, is a transcription factor known to be
involved in myogenesis and muscle regeneration (Déak et al.,
2014). Enc1 is an actin-binding protein, which is involved
in neuronal process formation (García-Calero and Puelles,
2005; Kim et al., 2009). Its expression has not been observed
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FIGURE 3 | The aggregate DLI of the three muscles for EAMG illustrate
disease progression by summing the absolute values of fold changes
of differentially regulated transcripts in each muscle.
TABLE 3 | Fold change comparison between real-time PCR and
microarray.
Gene symbol DIA EDL EOM
qPCR Array qPCR Array qPCR Array
ANKRD1 11.7 6.2 8.1 5.5 5.6 3.2
MT1A 4.2 4.7 4.8 8.2 5.3 3.4
CEBPD1 5.3 3.0 6.5 4.5 3.3 2.2
PDE4B 3.2 2.0 2.8 1.7 2.0 1.3
CTS L 2.8 1.8 2.7 2.8 2.2 1.4
CHRNA1 2.1 1.9 2.5 1.7 3.7 2.3
CTS E 1.9 1.2 0.9 1.0 7.5 7.6
CSRP3 5.9 2.4 5.4 3.3 3.0 1.4
NEU2 −3.2 −2.7 −3.8 −4.0 −1.9 −2.2
NFκB 1.1 1.0 1.8 1.3 1.3 1.0
PAX6 N/A 0.5 N/A 1.3 6.7 4.0
PLUNC N/A 0.9 N/A 1.0 4.1 3.0
RGS2 1.4 1.1 1.0 0.8 −1.8 −1.3
TRIM63 6.3 2.4 4.3 2.5 1.3 1.0
previously in muscle, and presumably, Enc1 would function
to aid recovery of damaged neuromuscular junctions. Errfi1
(also known as Mig6) is an inhibitor of epidermal growth
factor signaling and is increased with cell stress and positively
regulates cell growth. Elevation of Errfi1 expression would be
expected as a response to muscle injury, either from increased
oxidative metabolism or neuromuscular junction injury (Pante
et al., 2005). Our previous PTMG profiling study identified a
homolog of Mig6 to be upregulated across all three muscles.
Glipr2 is a signaling molecule, which has not been well-
characterized, but is upregulated in sciatic nerve injury from
experimental diabetes (Zhang et al., 2015). Glipr2 is involved
in transition of epithelial to mesenchymal cells by way of
epidermal growth factor signaling pathways (Huang et al.,
2013), which are also known to be involved in recovery from
muscle injury. Dyrk2 encodes a tyrosine kinase, which negatively
regulates growth of cardiac myocytes (Weiss et al., 2013),
and the reduced expression of Dyrk2 in EAMG would be
expected to promote recovery from injury. Galnt12 encodes
an acetylgalactosaminyl transferase and polymorphisms in the
gene are associated colonic cancer (Clarke et al., 2012; Wang
et al., 2014). The increased expression of Galnt12 likely enhances
protein modifications that may be involved in the regenerative
process.
Nfkbia (nuclear factor of kappa light polypeptide gene
enhancer in B-cells inhibitor, alpha) is a transcriptional
factor with increased expression among all three muscles
exclusive to EAMG. Nfkbia inhibits cell apoptosis by inhibition
of caspase. In rats, Nfkbia is decreased in diet-induced
obesity and hyperlipidemia. Nfkbia can inhibit NFκB by
direct binding and regulation of transcriptional responses to
NFκB, including cell adhesion, immune and proinflammatory
responses, apoptosis, differentiation and growth (Hotamisligil,
2006). In addition to its effects on contractility, Fkbp5
modulates NFκB activity and in tandem with Nfkbia would
reduce inflammatory signaling in muscle (Erlejman et al.,
2014).
In addition, to the primary categories of muscle repair and
immunosuppression, there were three gene changes that would
influence metabolism. The Dyrk2 gene product phosphorylates
glycogen synthase (Skurat and Dietrich, 2004) and therefore,
the gene’s down-regulation would be a response to a shift to
fatty acid oxidation (see discussion below). Pnpla2 encodes
a lipase that hydrolyzes fatty acids from triacylglycerol and
mutations of the gene produce a myopathy. The upregulation
of the gene’s expression is also in keeping with the overall
shift to fatty acid oxidation (Henriksson, 1995). This change
to oxidation is a reflection of decreased availability of glucose
and would further be reflected in a reduction of muscle force
generation. The reason for the reduced expression of the
two hemoglobin gene transcripts (Hbb, Hba-a1) in muscle is
not clear.
Gene Expression Changes Specific to
EAMG
Consistent with overall profile, alterations of genes involved in
metabolism were the most common category for EOM. The
gene encoding the alpha subunit of the acetylcholine receptor
was increased in response to EAMG in skeletal muscle an
EOM previously (Asher et al., 1990; Léger et al., 2006). We
evaluated expression of four genes by qPCR expressed at high
levels in EOM, three of which appear to be responsive to injury.
Pax6 is a transcriptional regulator involved in eye development
and during development influences muscle formation (Davis-
Silberman et al., 2005). Its increased expression in EOM suggests
that it may be responding to injury, perhaps through the
elevated activity of muscle satellite cells in EOM (McLoon
et al., 2004). Rgs2, a regulator of G-protein signaling, also
appears to be involved quiescent stem cell renewal of muscle
(Subramaniam et al., 2014). Cspr1, a member of the LIM
protein family, has many functions in skeletal and cardiac
muscle including myocyte differentiation (Vafiadaki et al.,
2015). Plunc is expressed in nasal epithelial tissue and has a
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bactericidal effects suggesting a role in innate immunity (Liu
et al., 2016). Its upregulation in EOM in response to EAMG
suggests a response to antibody-mediated injury but otherwise
is unclear.
Gene Expression Alterations Common to
All Muscles and PTMG
PTMG is produced by administration of either mono- or poly-
clonal antibody specifically directed toward the autoantigen, in
the present study the skeletal muscle AChR (Kusner et al., 2015).
The model mimics the final effector pathway of autoantibody
destruction observed in humans with MG. The onset of muscle
injury is rapid and is accompanied by muscle inflammation not
seen in the active model or the human disease. In our previous
study of PTMG of EDL, DIA, and EOM (Zhou et al., 2014), RNA
profiling demonstrated a greater number of gene alterations, a
preponderance of immune-related gene expression alterations,
and EOM had the greatest DLI. There were specific gene
alterations common among the three muscles and interestingly
among these, several were shared with our present RNA profile
of EAMG (Zhou et al., 2014). These ten genes were Ankrd1,
Gpnmb, Cebpd, Pdk4, Angptl4, Ddit4, Gadd45a, Mt1a, Fmo2, and
Fkbp5.
Evidence of Immunosuppressive Response across
Muscles
Ankrd1 has been found to be increased in response in
several forms of muscle injury, including denervation, motor
neuron disease, stretch, and starvation (Miller et al., 2003;
Wu et al., 2011; Calvo et al., 2012). Ankrd1 also down
regulates NFκB as an anti-inflammatory signal (Liu et al.,
2015), which would contribute to the lack of local muscle
inflammation in EAMG, while its increase in PTMG may
be a response to acute inflammation observed. Osteoactivin
(Gpnmb) is a type I transmembrane glycoprotein that is expressed
in numerous tissues including skeletal muscle. Osteoactivin
has immunosuppressive effects (Schwarzbich et al., 2012) and
promotes maintenance of innervation (Furochi et al., 2007),
these properties would aid recovery from injury by EAMG. In
contrast to the PTMG study in which an inflammatory infiltrate
was present, we can be confident that the source of Gpnmb
transcripts is from the skeletal muscle. The increase of Cebpd,
a transcriptional factor known to reduce pro-inflammatory
cytokines (Pedersen and Febbraio, 2008; Scheler et al., 2013),
would also serve to limit muscle inflammation in response to
EAMG (Moore et al., 2012). Increased expression of cortisone-
regulated target genes also would indicate a general anti-
inflammatory state, which would also be reflected in metabolic
alterations.
Metabolic Alterations Influenced by EAMG
The other genes in common across MG models and the three
muscles under study were primarily involved in metabolism.
At the time of euthanasia, rats were demonstrating weight loss,
however, in comparison an RNA profile of rat gastrocnemius
after fasting, the gene alterations observed with EAMG are
distinct (de Lange et al., 2004). The pyruvate dehydrogenase
kinase gene is a key regulatory enzyme in skeletal muscle involved
in switching the primary energy source from glucose to fatty
acids in response to physiological conditions. Transcription
of the PDK4 gene is activated by fasting in a tissue-specific
manner (Wende et al., 2005; Yumuk, 2006) and after both
short-term high-intensity and prolonged low-intensity exercise.
Angptl4 (an inhibitor of lipoprotein lipase) expression was
increased, and its protein product is directly involved in
reduction of glucose utilization, enhanced lipid metabolism,
and increased insulin sensitivity during fasting (Dutton and
Trayhurn, 2008; Staiger et al., 2009). Metallothioneins are low
molecular weight, cysteine–rich zinc binding proteins and serve
to protect cells after oxidative stress injury (Reinecke et al.,
2006). Mt1a is a metallothionein, which is induced in skeletal
muscle of animals in catabolic states and physiological stress
situations (Lecker et al., 2004), which also result in elevated
levels of glucocorticoids and reactive oxygen species. Another
metallothionein, Mt1e, was elevated among all muscles in the
present study, but not the PTMG investigation. The increase in
flavin-containing mono-oxygenase 2 (Fmo2) also would serve
as a response to an increase in reactive oxygen species in the
switch to fatty acid oxidation (Krueger and Williams, 2005).
These observations suggest that EAMG directly or indirectly
may increase intracellular reactive oxygen species with muscle
responding with a potential adaptive response to systemic
metabolic alterations. The uniform response to stress is further
confirmed by increased expression of Ddit4 and Gadd45a.
Ddit4 is a DNA-damage-inducible transcript, inhibits mTOR
(downstream kinase of IGF pathway) functional control of
cell growth in response to energy stress (Sofer et al., 2005;
Wang, 2006). Gadd45a is activated by physiological stress
and DNA damage serving to modulate cell cycle arrest and
apoptosis (Prosperi, 1997). Increased Cebpd expression occurs
with denervation and food deprivation (Allen et al., 2010; Zhang
et al., 2013). In skeletal muscle Cebpd expression would moderate
myostatin expression and potentially produce muscle atrophy
(Yang et al., 2005).
Muscle Contractility Gene Influences
The increase of Fkbp5 (FK506 binding protein) may serve to
moderate calcium activation through the ryanodine receptor
(Krueger and Williams, 2005). In PTMG, muscle contractility
is compromised to a greater extent than expected from
the neuromuscular transmission defect alone. An increase
in Fkbp5 would reduce influx of calcium and negatively
impact muscle contractility. Muscle force generation is also
reduced in isolated muscle preparations treated with sera
from patients with MG (Imai et al., 2011, 2012). In EDL,
Zfn28 was found to be increased. Zfn28 is a RING zinc
finger protein family member, which localizes to the Z-line
and M-line lattices of myofibrils. In vitro binding studies
indicate that Zfn28 binds to titin near the region responsible
for kinase activity. Since these family members can form
heterodimers, this suggests that these proteins may serve as
a link between titin kinase and microtubule-dependent signal
pathways in muscle (Ng et al., 2003). Alterations in the signaling
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complex could also moderate contractility through alterations in
elasticity.
Neu2 was the only gene reduced in expression among all
three muscles and common to the RNA profile of PTMG.
Neu2 encodes a glycohydrolytic enzyme that is primarily
expressed in mature muscle (Miyagi and Yamaguchi, 2012).
The function of Neu2 has not been well characterized but is
considered to enhance muscle regeneration and development,
and its reduced expression in EAMG may compromise muscle
repair.
RNA Profile across Muscles
Numerous clinical observations demonstrate a differential effect
of neuromuscular disorders on specific muscle groups. Our
previous RNA expression analysis of PTMG showed that EOM
had the greatest DLI, which we had considered consistent
with the greater susceptibility of EOM to disease observed
in human MG. In the PTMG, transcript alterations were
largely related to immune activity. In EAMG, EDL had the
greatest transcriptional response to EAMG but this was related
to preponderance of metabolic alterations. EOM given their
specialized function in moving the globe and small size
would not contribute to whole body metabolic control in
contrast to EDL and other large muscles, which are critical to
regulation of glucose, fatty acid, and amino acid synthesis and
utilization.
Regarding specific gene expression alterations of note, the
AChR subunit α-subunit was increased consistent with previous
EAMG investigations. The expression difference was likely
detectable in EOM because of its high innervation ratio
and the increased expression reserved to subsynaptic nuclei
(Hippenmeyer et al., 2007). Spp1 (osteopontin) was upregulated
in EOM. OPN is a glycosylated phosphoprotein originally
identified in bone matrix, but now found to be produced in
many cell types. OPN is considered a pro-inflammatory cytokine,
and increased levels have been associated with inflammatory
muscle disease (Urganus et al., 2009; Niewold et al., 2010; Kim
et al., 2012) and muscular dystrophy (Kyriakides et al., 2011).
Its elevated expression is in distinction from the upregulation
of an anti-inflammatory state of RNA profile, which would
support the contention that EOM has a unique immune
environment, which in certain conditions enhances susceptibility
to autoimmune and inflammatory disorders (Soltys et al.,
2008).
Metallothionein family members are highly induced by
catabolic states where found to be elevated across all muscle
groups (Sacheck et al., 2007). Foxo1a, a transcription factor, was
increased in EDL and diaphragm by EAMG and is also increased
in states of catabolism (Sacheck et al., 2007). Cathepsin L was
elevated in EDL with EAMG which is also the case for muscle
atrophy.
Clinical Relevance
As with any animal study there are limits in application
of results to human disease. The rat and human immune
systems possess unique characteristics, and the exogenous
administration of autoantigen with adjuvant does not
mimic the spontaneous development of the breakdown
in tolerance of the human disease (Losen et al., 2015).
However, the ultimate common pathway of antibody attack
with complement activation is shared between EAMG
and human MG. The subsequent influence of generalized
weakness on the animal and human also are likely to have
commonalities.
The EAMG rats developed moderate weight loss, which is
likely driving the gene expression changes related to metabolism.
The three muscles shared similar responses in shifting to
from glycolytic to oxidative metabolism. In keeping with this
alteration pathway the same response in terms of stress and
free radical metabolism pathways, and a number of nuclear
receptors target genes involved in lipid and glucose metabolism
were altered by EAMG. Cortisone or dexamethasone target genes
were induced and insulin-moderated pathways were inhibited.
This was true for EOM, which relies on glucose and lactate
for generation of energy (Porter et al., 2001; Andrade and
McMullen, 2006). These observations demonstrate that RNA
profiles related to metabolism undergo significant alterations
by EAMG.
In muscle, there are four pathways for protein degradation:
lysosomal proteases including the cathepsins; calcium-
dependent proteases; cytosolic ATP-dependent (proteasome);
and cytosolic ATP-independent proteolytic pathways. In
EDL and DIA FBXO32(atrogin-1) and Trim63(MuRF-1)
were upregulated, these two genes are E3 ubiquitin-ligase,
which are involved in ubiquitin-proteasome proteolysis
pathway and are markers of muscle atrophy (Clavel et al.,
2006; Edström et al., 2006). Their common transcription
factor, Foxo1a was also increased in expression (Léger et al.,
2006; Nakashima et al., 2006). Proteasome pathway related
genes were more prominently expressed in EDL compared
with DIA and EOM. EDL can be considered a “standard”
skeletal muscle, which participates in regulation of whole
body metabolism. These data suggest the EAMG leads to
accelerated proteolysis, which is also likely to occur among
patients with significant weakness. Since the active model of
EAMG more closely mimics MG in humans, it is likely that
metabolic alterations should be a focus of investigation in clinical
studies.
CONCLUSION
Our study demonstrates the complex alterations occurring on
a transcriptional level in response to the direct effects of
acetylcholine receptor antibody attack on the neuromuscular
junction as well as secondary influences on nerve-muscle
communication and development of weight loss. In our
investigation we cannot uncouple these effects. We show
that alterations in metabolism related genes occurs, an anti-
inflammatory response develops, and muscle repair programs
develop. Despite an expectation that EOM would have a greater
DLI, this was not the case indicating that the reasons for the
greater susceptibility of EOM to MG are not reflected in the
transcriptional profile.
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